IRLAB Competitors

Stocks . Sweden . 
Stock . IRLAB Therapeutics AB
IRLAB-A Stock  SEK 3.39  0.04  1.19%   
IRLAB Therapeutics competes with Sprint Bioscience, Intervacc, Fluicell, Galecto, and Bicycle Therapeutics; as well as few others. The company operates under Healthcare sector and is part of Biotechnology industry. Analyzing IRLAB Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of IRLAB Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out IRLAB Therapeutics Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of IRLAB Therapeutics competition on your existing holdings.
  
Hype
Prediction
LowEstimatedHigh
0.173.359.26
Details
Intrinsic
Valuation
LowRealHigh
0.163.229.13
Details
Naive
Forecast
LowNextHigh
0.094.3210.23
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.624.747.86
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as IRLAB Therapeutics. Your research has to be compared to or analyzed against IRLAB Therapeutics' peers to derive any actionable benefits. When done correctly, IRLAB Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in IRLAB Therapeutics.

IRLAB Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between IRLAB Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of IRLAB and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of IRLAB Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
BINV
+ 0.82
GLTO
BIOA-B
+ 0.7
VICO
BINV
+ 0.63
VICO
BIOA-B
+ 0.55
BINV
BCYC
+ 0.48
FLUI
BIOA-B
+ 0.48
GLTO
  
High negative correlations   
GLTO
- 0.77
FLUI
VICO
- 0.71
SPRINT
BINV
- 0.66
SPRINT
GLTO
- 0.53
SPRINT
BINV
- 0.52
FLUI
BIOA-B
- 0.34
SPRINT

Risk-Adjusted Indicators

There is a big difference between IRLAB Stock performing well and IRLAB Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze IRLAB Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

IRLAB Therapeutics Competitive Analysis

The better you understand IRLAB Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, IRLAB Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across IRLAB Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
IRLAB-A SPRINT IVACC FLUI GLTO BCYC CANTA VICO BINV BIOA-B
 1.19 
 3.39 
IRLAB
 1.96 
 0.52 
Sprint
 1.02 
 0.99 
Intervacc
 1.79 
 8.55 
Fluicell
 0.00 
 3.60 
Galecto
 2.92 
 8.31 
Bicycle
 17.23 
 3.13 
Cantargia
 0.13 
 7.80 
Vicore
 0.39 
 38.15 
BioInvent
 1.03 
 196.00 
BioArctic
Market Volatility
(90 Days Market Risk)
Very risky
Out of control
Extremely Dangerous
Slightly risky
Moderately volatile
Somewhat reliable
Out of control
Slightly risky
Not too volatile
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Weak
Very Weak
Good
Weak
OK
OK
OK
Insignificant
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Below Average
Quite High
Quite High
Low
Low
Below Average
Above Average
Low
Below Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Under Valued
Over Valued
Fairly Valued
Over Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Buy
Strong Buy
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Sell
Strong Sell
Cautious Hold
Strong Sell
Strong Sell
Cautious Hold
Cautious Hold
Cautious Hold
Current Ratio
9.19
2.69
12.16
2.3
10.98
9.88
16.19
19.83
2.73
5.62
Net Asset
472.45 M
79.14 M
329.39 M
26.98 M
17.13 M
956.87 M
600.24 M
451.17 M
1.45 B
897.73 M
Profit Margin
-1.69
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-0.14
-0.0486
EBITDA
55.62 M
(24.22 M)
(23.15 M)
(21.08 M)
(21.22 M)
(164.89 M)
(363.06 M)
(293.13 M)
(263.32 M)
(126.63 M)
Operating Margin
-1.68
-76.0
-4.77
-8.62
N/A
-7.04
N/A
N/A
-0.16
-0.0338
Current Valuation
1.74 B
24.98 M
1.26 B
49.13 M
(5.76 M)
(191.83 M)
34.5 M
1.22 B
1.16 B
26.19 B
Price To Book
6.24
2.61
5.02
4.86
0.38
0.8
1.11
8.67
1.4
32.29
Retained Earnings
N/A
(39 M)
N/A
N/A
(277.52 M)
(680.79 M)
(70 M)
N/A
N/A
N/A
Current Asset
N/A
25 M
N/A
N/A
N/A
103.53 M
30 M
N/A
56 M
N/A
Beta
0.16
1.32
1.07
1.96
1.32
1.47
1.67
0.59
0.3
0.61
Number Of Employees
31
34
13
19
5
305
27
23
93
61
Shares Outstanding
51.79 M
69.8 M
50.49 M
24.49 M
1.32 M
47.76 M
166.99 M
81.85 M
65.8 M
73.73 M
Cash Flow From Operations
128.64 M
(40.12 M)
(25.46 M)
(18.64 M)
(18.62 M)
(164.72 M)
(346.44 M)
(265.17 M)
(245.84 M)
(140.46 M)
Total Debt
3.57 M
N/A
222 K
N/A
73 K
9.49 M
N/A
320 K
21.53 M
7.79 M
Return On Equity
-0.28
-1.09
-0.17
-1.13
-0.88
-0.37
-0.69
-0.99
-0.0274
-0.0142
Z Score
88.2
N/A
N/A
N/A
N/A
N/A
N/A
N/A
55.2
N/A
Return On Asset
-0.15
-0.59
-0.0991
-0.49
-0.36
-0.22
-0.4
-0.49
-0.0192
-0.0055
Book Value Per Share
6.25
0.63
5.41
0.76
9.34
10.7
2.87
2.24
25.92
8.92
Number Of Shares Shorted
N/A
N/A
N/A
N/A
36.85 K
2.6 M
N/A
N/A
N/A
N/A
Current Liabilities
N/A
21 M
N/A
N/A
N/A
8.46 M
9 M
N/A
28 M
N/A
Total Asset
472.45 M
79.14 M
329.39 M
26.98 M
17.13 M
956.87 M
600.24 M
451.17 M
1.45 B
897.73 M
Debt To Equity
2.9
32.2
N/A
0.19
0.006
0.15
N/A
N/A
22.0
3.0
Target Price
200.0
32.0
95.0
N/A
6.0
26.27
20.33
69.6
81.0
393.2
Short Ratio
N/A
N/A
N/A
N/A
0.57
9.95
N/A
N/A
N/A
N/A
Shares Owned By Institutions
22.49
2.59
32.27
0.67
13.03
93.44
33.6
51.89
57.03
30.39
Market Capitalization
525.71 M
53.17 M
1.02 B
73.64 M
4.74 M
592.81 M
915.45 M
1.26 B
1.99 B
26.34 B
Price To Earning
N/A
32.79
N/A
N/A
N/A
-3.31
2.12
163.82
-9.49
12.95
Price To Earnings To Growth
N/A
N/A
N/A
N/A
-0.01
N/A
N/A
N/A
N/A
N/A
Price To Sales
33.49
27.09
125.83
10.51
N/A
23.05
N/A
N/A
7.25
111.27
Net Income
51.78 M
(25.08 M)
(29.38 M)
(21.69 M)
(21.44 M)
(169.03 M)
(370.27 M)
(296.48 M)
(278.44 M)
(119.79 M)
Earnings Per Share
0.81
-0.75
-0.67
-1.68
-15.4
-3.16
-4.11
-4.76
-4.55
0.31
Shares Owned By Insiders
38.63
35.31
14.49
11.2
3.59
1.46
9.1
16.14
11.1
48.4
Revenue
207.78 M
35.11 M
5.24 M
2.6 M
N/A
35.27 M
N/A
N/A
19.38 M
23.15 M
Working Capital
N/A
4 M
N/A
N/A
15.64 M
861.38 M
21 M
N/A
28 M
N/A
Cash And Equivalents
401.9 M
13.82 M
148.98 M
20.69 M
79.03 M
372.77 M
842.44 M
215.97 M
28.46 M
848.4 M
Cash Per Share
2.89
1.19
2.97
1.45
3.11
12.56
8.41
5.1
0.08
13.84
Gross Profit
126.05 M
24.59 M
6.25 M
1.89 M
N/A
(171.57 M)
N/A
N/A
19.38 M
155.53 M
Day Typical Price
3.36
0.52
0.98
8.45
3.76
8.56
3.06
7.8
38.22
195.0
Accumulation Distribution
12071.88
344.4
0.04
451.53
10452.01
26918.42
2.6 M
6011.29
0.0233
2036.14
Market Facilitation Index
0.0
0.0
0.04
2.0E-4
0.0
0.0
N/A
0.0
0.9
1.0E-4
Daily Balance Of Power
0.1818
1.0
0.25
0.1667
N/A
(0.32)
0.6765
0.0357
(0.17)
0.4
Period Momentum Indicator
0.04
0.01
0.01
0.15
N/A
(0.25)
0.46
0.01
(0.15)
2.0
Rate Of Daily Change
1.01
1.02
1.01
1.02
1.0
0.97
1.17
1.0
1.0
1.01
Day Median Price
3.34
0.52
0.98
8.4
3.84
8.69
3.03
7.8
38.25
194.5
Price Action Indicator
0.07
0.01
0.015
0.23
(0.24)
(0.50)
0.33
0.005
(0.18)
2.5
Coefficient Of Variation
(621.31)
(3,533)
1397.57
(639.40)
622.47
1162.1
1003.38
1063.9
835.18
985.83
Mean Deviation
2.77
3.87
2.52
2.74
2.77
3.18
8.67
2.69
2.8
2.14
Jensen Alpha
(0.88)
(0.12)
0.1323
(0.56)
0.442
0.1304
3.84
0.2271
0.3593
0.2966
Total Risk Alpha
(1.73)
(0.94)
(0.26)
(1.07)
0.0712
(0.26)
(1.30)
(0.17)
(0.10)
(0.13)
Sortino Ratio
N/A
N/A
0.041
N/A
0.112
0.0575
0.4769
0.0715
0.0946
0.0598
Downside Variance
N/A
N/A
8.19
N/A
19.25
19.58
40.89
7.46
18.06
9.38
Standard Deviation
5.73
5.55
3.61
3.58
3.94
4.59
32.01
3.57
4.53
3.19
Kurtosis
33.68
2.5
4.04
0.7953
1.21
4.9
62.24
2.12
7.19
4.39
Potential Upside
4.7
7.58
6.45
7.14
7.14
6.54
8.46
7.13
6.05
5.08
Treynor Ratio
2.32
0.4534
0.2801
7.09
0.4516
0.1977
(0.63)
0.4308
0.4015
2.37
Maximum Drawdown
49.91
28.27
22.18
16.68
20.14
34.57
259.23
20.96
23.77
23.15
Variance
32.8
30.75
13.02
12.8
15.49
21.08
1024.88
12.78
20.56
10.2
Market Risk Adjusted Performance
2.33
0.4634
0.2901
7.1
0.4616
0.2077
(0.62)
0.4408
0.4115
2.38
Risk Adjusted Performance
(0.14)
(0.02)
0.0742
(0.14)
0.1577
0.0883
0.1028
0.0952
0.1198
0.1018
Skewness
(4.84)
(0.78)
1.33
0.6995
(0.19)
(0.24)
7.77
1.07
0.5087
(0.18)
Semi Deviation
N/A
N/A
2.5
N/A
3.55
4.24
4.84
2.48
3.71
2.78
Information Ratio
(0.19)
(0.05)
0.0325
(0.20)
0.1249
0.0554
0.0953
0.0546
0.0887
0.0573
Value At Risk
(4.56)
(10.64)
(4.10)
(6.31)
(7.59)
(5.41)
(8.13)
(4.23)
(4.67)
(3.19)
Expected Short fall
N/A
N/A
(3.46)
N/A
(3.32)
(3.57)
(13.13)
(3.28)
(3.06)
(2.44)
Downside Deviation
N/A
N/A
2.86
N/A
4.39
4.43
6.39
2.73
4.25
3.06
Semi Variance
N/A
N/A
6.24
N/A
12.6
17.99
23.47
6.14
13.79
7.7

IRLAB Therapeutics Competition Performance Charts

Five steps to successful analysis of IRLAB Therapeutics Competition

IRLAB Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by IRLAB Therapeutics in relation to its competition. IRLAB Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of IRLAB Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact IRLAB Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to IRLAB Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your IRLAB Therapeutics position

In addition to having IRLAB Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run SRI Sustainable Growth Thematic Idea Now

SRI Sustainable Growth
SRI Sustainable Growth Theme
Socially responsible investments that include companies making a positive, sustainable or social impact and exclude those making a negative impact. The SRI Sustainable Growth theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize SRI Sustainable Growth Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in IRLAB Stock

IRLAB Therapeutics financial ratios help investors to determine whether IRLAB Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in IRLAB with respect to the benefits of owning IRLAB Therapeutics security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY